Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood 2020 Jul 02;136(1):137-139
Date
05/28/2020Pubmed ID
32457999Pubmed Central ID
PMC7332891DOI
10.1182/blood.2020006216Scopus ID
2-s2.0-85087529450 (requires institutional sign-in at Scopus site) 53 CitationsAuthor List
Frigault MJ, Nikiforow S, Mansour MK, Hu ZH, Horowitz MM, Riches ML, Hematti P, Turtle CJ, Zhang MJ, Perales MA, Pasquini MCAuthors
Peiman Hematti MD Professor in the Medicine department at Medical College of WisconsinMary M. Horowitz MD, MS Professor in the Medicine department at Medical College of Wisconsin
Marcelo C. Pasquini MD, MS Professor in the Medicine department at Medical College of Wisconsin
Mei-Jie Zhang PhD Professor in the Institute for Health and Equity department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AgedAged, 80 and over
Antibodies, Monoclonal, Humanized
Betacoronavirus
Coronavirus Infections
Female
Hematologic Neoplasms
Humans
Immunotherapy, Adoptive
Male
Middle Aged
Pandemics
Pneumonia, Viral
Risk Factors